London-based pharmaceutical company GSK revealed clinically meaningful phase 3 results from its respiratory syncytial virus vaccine candidate intended for adults 60 and older.
The vaccine uses an antigen-plus-adjuvant combination that the company said may help overcome the natural age-related decline in immunity that makes it more difficult to protect older adults from RSV disease.
"RSV remains one of the few major infectious diseases without a vaccine, and these data have the potential to meaningfully impact the treatment of RSV and may reduce the 360,000 hospitalizations and more than 24,000 deaths worldwide each year," GSK's chief scientific officer and president of research and development, Hal Barron, MD, said in a June 10 press release.